TAMARA O'NAN: Open Payments
NPI 1477837862 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,881 in 200 payments from 23 companies in 2025. Trend: 2023 $2,702 · 2024 $3,624 · 2025 $4,881
Food & beverage: $4,881
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $607 |
| Vanda Pharmaceuticals Inc. | 17 | $581 |
| Neurocrine BioSciences, Inc. | 16 | $489 |
| E.R. Squibb & Sons, L.L.C. | 10 | $382 |
| Janssen Pharmaceuticals, Inc | 7 | $337 |
| Axsome Therapeutics, Inc. | 16 | $336 |
| ABBVIE INC. | 16 | $258 |
| Noven Therapeutics, LLC | 11 | $240 |
| Otsuka America Pharmaceutical, Inc. | 11 | $238 |
| Alkermes, Inc. | 11 | $232 |
Products named: CAPLYTA, HETLIOZ, INGREZZA, COBENFY, Auvelity, SPRAVATO, VRAYLAR, Xelstrym.
Industry payments across CA — which companies pay providers there.
